Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19
Authors: Claudia N. Paiva, Daniel V. Tausk
Journal: Annals of Internal Medicine (2021)

LettersMarch 2021Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19Claudia N. Paiva, PhD, Daniel V. Tausk, PhDClaudia N. Paiva, PhDUniversidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilSearch for more papers by this author, Daniel V. Tausk, PhDUniversidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-1424 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: We read Skipper and colleagues' article (1) with interest but disagree with some of their conclusions, which we believe could not be made from the data shown. Supplement Table 3 concerns medication adherence. It states that in the hydroxychloroquine (HCQ) group, 157 patients received 100% of the tablets; 8 patients received 75% to 99% of the tablets; 16 patients received fewer than 75% of the tablets; and 22 patients never started medication. These values sum to 203 patients. In the placebo group, the number of patients (166 + 3 + 12 + 13, respectively) sums to 194.Supplement Table 2 analyzes ...References1. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19. A randomized trial. Ann Intern Med. 2020;173:623-31. doi:10.7326/M20-4207 LinkGoogle Scholar2. Dodd S, White IR, Williamson P. Nonadherence to treatment protocol in published randomised controlled trials: a review. Trials. 2012;13:84. [PMID: 22709676] doi:10.1186/1745-6215-13-84 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Claudia N. Paiva, PhD; Daniel V. Tausk, PhDAffiliations: Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilDisclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-1424. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHydroxychloroquine in Nonhospitalized Adults With Early COVID-19 Caleb P. Skipper , Katelyn A. Pastick , Nicole W. Engen , Ananta S. Bangdiwala , Mahsa Abassi , Sarah M. Lofgren , Darlisha A. Williams , Elizabeth C. Okafor , Matthew F. Pullen , Melanie R. Nicol , Alanna A. Nascene , Kathy H. Hullsiek , Matthew P. Cheng , Darlette Luke , Sylvain A. Lother , Lauren J. MacKenzie , Glen Drobot , Lauren E. Kelly , Ilan S. Schwartz , Ryan Zarychanski , Emily G. McDonald , Todd C. Lee , Radha Rajasingham , and David R. Boulware Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 Bruno Luís de Castro Araujo Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 Caleb P. Skipper , David R. Boulware Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 Anusuya Bhattacharyya , Phulen Sarma , Hardeep Kaur , Bikash Medhi Metrics March 2021Volume 174, Issue 3 Page: 432-433 ePublished: 16 March 2021 Issue Published: March 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...